Simultaneous quantification of thalidomide, lenalidomide and pomadomide in plasma by LC-MS/MS

Wang, Bin; Qiang, Wanting; Jia, Yi; Gao, Shouhong; Meng, Bosu; Mu, Yuhui; Wang, Bolong; Wang, Zhipeng; Xia, Tao

doi:10.1016/j.vascn.2023.107250

Cited by 2 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The developed method was validated according to the current bioanalytical guidelines from the U.S. Food and Drug Administration (FDA) and China Pharmacopoeia (version 2020). The following items were validated: specificity, linearity, interday and intraday precision and accuracy, linearity, matrix effect and recovery, carry-over, dilution effect, and stability [ 20 , 21 ].…”

Section: Methodsmentioning

confidence: 99%

A Simple and Rapid LC-MS/MS Method for the Quantification of Nirmatrelvir/Ritonavir in Plasma of Patients with COVID-19

Zhu,

Li,

Dai

et al. 2024

International Journal of Analytical Chemistry

Self Cite

View full text Add to dashboard Cite

The combined prescriptions of nirmatrelvir/ritonavir and other drugs are limited due to potential drug-drug interactions, so therapeutic drug monitoring (TDM) becomes particularly important. In this study, a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was established for determination of the nirmatrelvir/ritonavir in plasma of patients with COVID-19, providing technical and theoretical support for the TDM. Plasma samples were processed by protein precipitation using acetonitrile, and analytes were separated on an Agilent Poroshell 120 SB-C18 (2.1 × 75 mm, 2.7 μm) column at 35°C. Acetonitrile and 0.1% formic acid in water (52 : 48) were utilized as the mobile phases at a flow rate of 0.3 mL/min. In the multiple reaction monitoring (MRM) mode, nirmatrelvir and ritonavir were monitored using precursor/product ions: m/z 500.2/110.1 and 721.3/296.1, respectively, with selinexor as the internal standard. The linear range of both analytes was 2.0 ng/mL to 5000 ng/mL with good inter- and intraday precision and accuracy, and the recovery was 92.0%–107% for nirmatrelvir and 85.7%–106% for ritonavir. Finally, this method was successfully applied to monitor the exposure levels of nirmatrelvir/ritonavir in plasma samples from hemodialysis patients.

show abstract

Section: Methodsmentioning

confidence: 99%